ASTRAZENECA PLC |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12,038 GBX | -0.40% |
|
-4.19% | +13.49% |
| 02/07 | ASTRAZENECA : Jefferies reaffirms its Neutral rating | ZD |
| 02/07 | Deutsche Bank cuts Quilter, ups Polar Capital | AN |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
Pharmaceuticals
Calendar
25/07/2024
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
153.2
USD
Average target price
174.6
USD
Spread / Average Target
+13.92%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +13.49% | 238B | |
| +55.55% | 816B | |
| +40.77% | 634B | |
| -6.83% | 351B | |
| +17.15% | 323B | |
| +7.09% | 293B | |
| +1.47% | 222B | |
| +13.61% | 218B | |
| +7.87% | 167B | |
| -3.33% | 158B |
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- AstraZeneca's Combination Formulation for Endometrial Cancer Gains Support for EU Application
